(2S,3S)-3-(2-hydroxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine | 145742-29-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (2S,3S)-3-(2-hydroxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine
• 英文别名: CP-125,611；(2S,3S)-3-(2-hydroxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine；Unii-J41vun24GM；2-[[[(2S,3S)-2-phenylpiperidin-3-yl]amino]methyl]-4-(trifluoromethoxy)phenol
• CAS: 145742-29-6
• 化学式: C₁₉H₂₁F₃N₂O₂
• 分子量: 366.383
• InChiKey: IZRHKURJIQCXMT-WMZOPIPTSA-N

物化性质

• 沸点：
  465.9±45.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  53.5
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (2S,3S)-N-[(2-甲氧基苯基)甲基]-2-苯基-3-哌啶胺 在 platinum(IV) oxide 氢气 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 (2S,3S)-3-(2-hydroxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine
  参考文献：
  名称：

  Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist

  摘要：

  The synthesis and SAR of benzylamine side chain analogs of the NK-1 receptor antagonist CP-99,994 are described. The 5-trifluoromethoxy analog, CP-122,721, shows superior in vivo blockade of NK-1 receptor mediated responses. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00012-2

文献信息

• Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
  申请人：——

  公开号：US20020035147A1

  公开（公告）日：2002-03-21

  The present invention relates to methods of treating various CNS and other disorders by adminstering fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, by administering compounds of the formula 1 wherein Q, X 1 , X 2 and X 3 are as defined below, and their pharmaceutically acceptable salts.

  本发明涉及通过给予含氮杂环化合物的氟烷氧基苄胺衍生物来治疗各种中枢神经系统和其他疾病的方法，具体地，通过给予以下公式中的化合物来治疗： 1 其中Q、X 1 、X 2 和X 3 如下所定义，并且它们的药用盐。
• New pharmaceutical combinations for NOS inhibitors
  申请人：Pfizer Inc

  公开号：US20040229911A1

  公开（公告）日：2004-11-18

  The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.

  本发明涉及表现为一氧化氮合酶（NOS）抑制剂活性的化合物的新药物用途。具体地，涉及使用NOS抑制剂，特别是选择性神经元NOS（nNOS）抑制剂，单独或与另一种活性剂联合使用，特别是SSRI或NK-1受体拮抗剂，用于治疗可以通过改变昼夜节律来达到或促进治疗的疾病或病况。这些疾病和病况的例子包括失明、肥胖症、季节性情感障碍、双相情感障碍、时差反应、昼夜节律睡眠障碍、睡眠剥夺、睡眠障碍、REM睡眠障碍、嗜睡症、睡眠-觉醒周期障碍、嗜睡症和与轮班工作或不规则工作时间表相关的睡眠障碍、夜尿症和不宁腿综合症。
• [EN] NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS<br/>[FR] NOUVELLES COMBINAISONS PHARMACEUTIQUES POUR LES INHIBITEURS DE NOS
  申请人：PFIZER PROD INC

  公开号：WO2000071107A2

  公开（公告）日：2000-11-30

  The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.

  本发明涉及表现为一氧化氮合酶（NOS）抑制剂的化合物的新药物用途。具体而言，涉及使用NOS抑制剂，特别是选择性神经元NOS（nNOS）抑制剂，单独或与另一活性剂，特别是SSRI或NK-1受体拮抗剂结合使用，治疗可以通过改变昼夜节律来实现或促进的疾病或状况。这些疾病和状况的例子包括失明，肥胖症，季节性情感障碍，双相情感障碍，时差反应，昼夜节律睡眠障碍，睡眠剥夺，睡眠障碍，REM睡眠障碍，嗜睡症，睡眠-清醒周期障碍，嗜睡症和与轮班或不规则工作时间表相关的睡眠障碍；夜尿症和不安腿综合症。
• Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
  申请人：Lowe Adams John

  公开号：US20050256162A1

  公开（公告）日：2005-11-17

  The present invention relates to novel fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, to compounds of the formula wherein Q, X 1 , X 2 and X 3 are as defined below. These novel compounds are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.

  本发明涉及一种新型含氮杂环化合物的氟烷氧基苯基氨基衍生物，具体地，涉及以下式子的化合物：其中Q、X1、X2和X3如下所定义。这些新型化合物在治疗炎症和中枢神经系统疾病以及其他疾病方面具有用途。
• Fluoroalkyoxybenzylamino derivatives of nitrogen containing heterocycles
  申请人：——

  公开号：US20030199540A1

  公开（公告）日：2003-10-23

  The present invention relates to novel fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, to compounds of the formula 1 wherein Q, X 1 , X 2 and X 3 are as defined below. These novel compounds are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.

  本发明涉及一种新型含氮杂环化合物的氟烷氧基苯基氨基衍生物，具体地，涉及式1的化合物，其中Q、X1、X2和X3如下所定义。这些新型化合物在治疗炎症和中枢神经系统疾病以及其他疾病方面是有用的。